Formulation and Evaluation of Hematinic Syrup Containing Iron, Vitamin B12 and Folic Acid

Abstract

Hematological disorders, particularly iron deficiency and megaloblastic anemia, remain a significant global health concern requiring effective and patient-compliant therapeutic interventions. The present study focuses on the formulation and evaluation of a hematinic syrup containing Iron, Vitamin B12, and Folic Acid to provide a synergistic approach for the management of anemia. The syrup was formulated using commonly available pharmaceutical excipients including sucrose as a sweetening agent, glycerin as a co-solvent, and methylparaben as a preservative, employing a simple and reproducible method suitable for laboratory-scale preparation.The prepared formulation was evaluated for various physicochemical parameters such as organoleptic properties (color, odor, taste), pH, viscosity, specific gravity, and drug content uniformity. The pH of the formulation was maintained within an acceptable range (4.5–5.5) to ensure stability and compatibility of the active ingredients. Viscosity measurements indicated appropriate flow characteristics, ensuring ease of administration and dose accuracy. The formulation exhibited good clarity, stability, and absence of precipitation, indicating proper solubilization and compatibility of ingredients.Preliminary stability studies conducted under room temperature conditions demonstrated that the formulation retained its physical appearance and drug content without significant degradation over the study period. The presence of iron, vitamin B12, and folic acid in combination provided a comprehensive therapeutic approach by supporting hemoglobin synthesis, red blood cell maturation, and DNA synthesis.The results of the study suggest that the developed hematinic syrup is stable, effective, and suitable for oral administration, particularly in pediatric and geriatric populations. The formulation approach adopted in this study is simple, cost-effective, and scalable, making it a viable option for further pharmaceutical development. This research highlights the importance of excipient selection and formulation optimization in developing efficient hematinic preparations

Keywords

Introduction

Anemia is one of the most widespread nutritional deficiency disorders affecting millions of people worldwide, particularly in developing countries. It is characterized by a decrease in hemoglobin concentration, red blood cell count, or oxygen-carrying capacity of blood, leading to symptoms such as fatigue, weakness, dizziness, and impaired cognitive function. Among the various types of anemia, iron deficiency anemia is the most prevalent, followed by megaloblastic anemia caused by deficiencies of essential vitamins such as Vitamin B12 and Folic Acid. These micronutrients play a critical role in erythropoiesis, DNA synthesis, and proper maturation of red blood cells.

Iron is a fundamental component of hemoglobin and is required for oxygen transport in the body. Inadequate iron intake, poor absorption, chronic blood loss, or increased physiological demand during pregnancy and growth periods can lead to iron deficiency. Vitamin B12 and folic acid are equally important as they are involved in nucleic acid synthesis and cell division. Deficiency of these vitamins results in the production of large, immature red blood cells, leading to megaloblastic anemia. Therefore, a combination therapy containing iron, vitamin B12, and folic acid is widely used for the effective management and prevention of anemia.

Among the various dosage forms available for hematinic therapy, oral liquid formulations such as syrups are highly preferred, especially for pediatric and geriatric patients. Syrups offer several advantages including ease of administration, improved patient compliance, rapid absorption, and flexibility in dose adjustment. Additionally, liquid dosage forms eliminate the need for disintegration and dissolution processes required in solid dosage forms, thereby enhancing the onset of therapeutic action. However, formulation of hematinic syrups presents several challenges such as stability of active ingredients, palatability, viscosity control, and prevention of oxidation, particularly in the case of iron salts.

The selection of suitable excipients plays a crucial role in the formulation of stable and effective hematinic syrups. Sweetening agents such as sucrose or sorbitol are used to improve taste, while flavoring agents enhance patient acceptability. Preservatives like methylparaben and propylparaben are incorporated to prevent microbial growth, especially in aqueous formulations. Stabilizers and antioxidants may also be added to protect sensitive components such as vitamin B12 from degradation. The formulation must also ensure uniform distribution of active ingredients to maintain dose accuracy throughout the product's shelf life.

From a pharmaceutical perspective, the development of a hematinic syrup requires careful consideration of physicochemical properties such as pH, viscosity, clarity, and compatibility of ingredients. Iron salts, for instance, can interact with other components and may lead to precipitation or color changes, which can affect product stability and patient acceptance. Similarly, vitamin B12 is sensitive to light and heat, requiring appropriate storage conditions and formulation strategies to maintain its potency. Therefore, a systematic approach to formulation and evaluation is essential to ensure the quality, safety, and efficacy of the final product.

Evaluation of hematinic syrups involves various quality control parameters including physical appearance, pH, viscosity, specific gravity, drug content, and stability studies. These parameters help in assessing the uniformity, consistency, and performance of the formulation. Stability studies, in particular, are important to determine the shelf life of the product and to ensure that the active ingredients remain within acceptable limits over time.

Despite the availability of numerous commercial hematinic formulations, there is a continuous need for developing cost-effective, stable, and patient-friendly formulations, especially in resource-limited settings. Academic research plays a vital role in exploring simple and reproducible formulation techniques that can be implemented at the laboratory level and scaled up for industrial production.

2. MATERIALS AND METHODS

Materials

The active pharmaceutical ingredients used in the formulation of hematinic syrup included Iron (as ferrous sulfate), Vitamin B12, and Folic Acid. Ferrous sulfate was selected as the iron source due to its high bioavailability and widespread use in oral hematinic preparations. Vitamin B12 and folic acid were included to support erythropoiesis and prevent megaloblastic anemia.

Excipients used in the formulation included sucrose (as a sweetening agent and viscosity enhancer), glycerin (as a co-solvent and humectant), methylparaben and propylparaben (as preservatives), citric acid (as a pH adjuster), and suitable flavoring agents (orange flavor) to improve palatability. Purified water was used as the vehicle for syrup preparation. All chemicals and reagents used were of analytical grade and complied with pharmacopeial standards.

2.2 Formulation of Hematinic Syrup

The hematinic syrup was prepared using a simple solution method suitable for laboratory-scale production. The composition of the formulation is given in Table 1.

Table 1: Formulation Composition of Hematinic Syrup (per 100 mL)

2.3 Method of Preparation

The hematinic syrup was prepared by the solution method using the following steps:

1. Preparation of Sugar Syrup Base
   Accurately weighed sucrose was dissolved in approximately 50 mL of purified water with continuous stirring and gentle heating (not exceeding 60°C) to form a clear syrup base.
2. Preparation of Preservative Solution
   Methylparaben and propylparaben were dissolved in a small quantity of warm glycerin to enhance solubility and then added to the sugar syrup with constant stirring.
3. Dissolution of Active Ingredients
   Ferrous sulfate was dissolved separately in a small volume of purified water. Folic acid was dissolved with mild heating, while vitamin B12 was dissolved carefully under light-protected conditions due to its sensitivity.
4. Mixing of Components
   The drug solutions were gradually added to the syrup base with continuous stirring to ensure uniform distribution of active ingredients.
5. Addition of Excipients
   Citric acid was added to adjust the pH of the formulation in the range of 4.5–5.5. Flavoring agent was then incorporated to improve taste and acceptability.
6. Make-up Volume
   The final volume was adjusted to 100 mL using purified water, and the solution was mixed thoroughly.
7. Filtration and Packaging
   The prepared syrup was filtered to remove any particulate matter and filled into amber-colored bottles to protect light-sensitive components.

2.4 Evaluation of Hematinic Syrup

The prepared formulation was evaluated for the following parameters:

2.4.1 Organoleptic Properties

The syrup was visually inspected for color, clarity, odor, and taste to ensure patient acceptability.

2.4.2 pH Determination

The pH of the syrup was measured using a calibrated digital pH meter to ensure stability and compatibility of ingredients.

2.4.3 Viscosity

Viscosity was determined using a Brookfield viscometer to evaluate the flow properties of the formulation.

2.4.4 Specific Gravity

Specific gravity was measured using a pycnometer to assess the density and uniformity of the syrup.

2.4.5 Drug Content Uniformity

The drug content of iron, vitamin B12, and folic acid was analyzed using suitable analytical methods (UV-visible spectrophotometry) to ensure uniform distribution.

2.4.6 Stability Studies

The formulation was subjected to short-term stability studies at room temperature and accelerated conditions to evaluate any changes in physical appearance, pH, and drug content over time.

2.5 Statistical Analysis

All experimental results were expressed as mean ± standard deviation (SD) based on triplicate determinations. The data obtained were analyzed to assess the reproducibility and reliability of the formulation.

3. RESULTS AND DISCUSSION

The formulated hematinic syrup containing Iron (as ferrous sulfate), Vitamin B12, and Folic Acid was successfully prepared using the solution method. The formulation was subjected to various physicochemical evaluations to assess its quality, stability, and suitability for oral administration. The results obtained are discussed in detail below.

3.1 Organoleptic Properties

The prepared syrup was evaluated visually for color, clarity, odor, and taste, which are important parameters for patient compliance, especially in pediatric and geriatric populations.

Table 2: Organoleptic Evaluation

The reddish-brown color is attributed to the presence of ferrous sulfate, while the addition of flavoring agents effectively masked the unpleasant metallic taste of iron. The formulation remained clear without any precipitation, indicating proper solubilization and compatibility of ingredients.

3.2 pH Determination

The pH of the syrup was found to be 4.8 ± 0.1, which lies within the acceptable range for hematinic formulations. Maintaining slightly acidic pH is essential for:

• Enhancing the stability of iron salts
• Preventing precipitation
• Improving palatability

The use of citric acid as a pH adjuster proved effective in maintaining the desired pH range.

3.3 Viscosity

Viscosity of the syrup was measured using a Brookfield viscometer and was found to be:

68.5 ± 2.3 cP

This viscosity indicates:

• Good pourability
• Ease of administration
• Adequate thickness for a syrup

The presence of sucrose contributed significantly to viscosity, ensuring uniform dosing and improved mouthfeel.

3.4 Specific Gravity

The specific gravity of the formulation was found to be:

1.21 ± 0.02

This value is consistent with standard syrup formulations and confirms uniform distribution of dissolved solids within the formulation.

3.5 Drug Content Uniformity

Drug content analysis was performed to ensure uniform distribution of active ingredients throughout the formulation.

Table 3: Drug Content Analysis

3.6 Stability Studies

Short-term stability studies were conducted over a period of 30 days under room temperature conditions.

Table 4: Stability Study Results

The formulation showed:

• No significant change in physical appearance
• Minimal variation in pH
• Negligible loss of drug content

This indicates good stability of the formulation under normal storage conditions.

The results obtained from the evaluation of hematinic syrup clearly demonstrate that the formulation was successfully developed with acceptable physicochemical properties. The solution method used for preparation proved to be simple, reproducible, and suitable for laboratory-scale formulation. The selection of excipients played a crucial role in achieving a stable and palatable formulation.

Sucrose not only acted as a sweetening agent but also contributed to viscosity and stability of the formulation. Glycerin improved solubility of preservatives and enhanced mouthfeel. The use of methylparaben and propylparaben effectively prevented microbial growth, ensuring product safety. Citric acid helped maintain an acidic pH, which is essential for the stability of iron and prevention of oxidation.

One of the major challenges in hematinic syrup formulation is masking the metallic taste of iron. This was successfully managed by the addition of flavoring agents and sweeteners, although a slight aftertaste remained, which is common in iron-containing preparations. The absence of precipitation and clarity of the solution indicate good compatibility among formulation components.

The drug content results confirmed that the formulation process did not lead to degradation of active ingredients. Stability studies further validated the robustness of the formulation, showing that it can maintain its quality over time.

Overall, the developed hematinic syrup meets the essential criteria of an ideal oral liquid formulation, including stability, uniformity, palatability, and ease of administration. The results are comparable with standard pharmaceutical preparations and support the feasibility of this formulation approach for academic and potential industrial applications.

CONCLUSION

The present study successfully demonstrated the formulation and comprehensive evaluation of a hematinic syrup containing Iron (as ferrous sulfate), Vitamin B12, and Folic Acid using a simple and reproducible solution method suitable for laboratory-scale preparation. The primary objective of this research was to develop a stable, palatable, and effective oral liquid dosage form capable of addressing nutritional deficiencies associated with anemia while ensuring patient compliance and ease of administration.

The formulation strategy adopted in this study proved to be effective in overcoming common challenges associated with hematinic syrups, particularly issues related to solubility, stability, taste masking, and compatibility of active ingredients. The use of sucrose as a sweetening and viscosity-enhancing agent significantly improved the organoleptic properties of the formulation, making it more acceptable for oral administration. Glycerin acted as an efficient co-solvent and humectant, facilitating the dissolution of preservatives and contributing to improved mouthfeel. The incorporation of methylparaben and propylparaben ensured microbial stability of the aqueous formulation, which is critical for maintaining product safety during storage.

The physicochemical evaluation of the prepared syrup confirmed that all parameters were within acceptable limits. The formulation exhibited a clear appearance, appropriate viscosity, and a slightly acidic pH, which is essential for maintaining the stability of iron salts and preventing precipitation. The drug content analysis demonstrated uniform distribution of active ingredients throughout the formulation, with values falling within pharmacopeial limits. This indicates the reliability and reproducibility of the formulation method used in the study.

One of the key findings of this research is the successful stabilization of multiple active ingredients within a single formulation. Iron, vitamin B12, and folic acid each have distinct physicochemical characteristics and stability profiles, which can pose challenges when combined. However, careful selection of excipients and optimization of formulation conditions ensured compatibility and prevented degradation. The slightly acidic pH maintained by citric acid played a crucial role in preserving the integrity of iron while also supporting the stability of other components.

The stability studies conducted over the evaluation period further confirmed that the formulation remained physically and chemically stable, with no significant changes in appearance, pH, or drug content. The absence of precipitation or phase separation indicates good solubilization and compatibility among the ingredients. These findings suggest that the developed formulation has the potential for acceptable shelf life under normal storage conditions.

From a therapeutic perspective, the combination of iron, vitamin B12, and folic acid provides a comprehensive approach to the management of anemia by addressing multiple pathways involved in red blood cell production. Iron supports hemoglobin synthesis, while vitamin B12 and folic acid are essential for DNA synthesis and maturation of erythrocytes. Therefore, the formulated hematinic syrup can be considered an effective and synergistic preparation for the prevention and treatment of anemia, particularly in populations at high risk such as children, pregnant women, and elderly individuals.

The simplicity and cost-effectiveness of the formulation method make it highly suitable for academic research and small-scale pharmaceutical development. The use of readily available excipients and straightforward preparation techniques ensures that the formulation can be easily reproduced in laboratory settings without the need for sophisticated equipment. This aspect is particularly valuable in educational institutions where resources may be limited.

Despite the successful outcomes, certain limitations of the study should be acknowledged. The evaluation was limited to physicochemical parameters and short-term stability studies. Further investigations involving long-term stability studies, microbial limit tests, and in vivo bioavailability studies are necessary to fully establish the therapeutic efficacy and commercial viability of the formulation. Additionally, optimization of flavoring agents could further improve palatability by minimizing the residual metallic taste associated with iron.

In conclusion, the present study successfully formulated a stable, effective, and patient-friendly hematinic syrup using iron, vitamin B12, and folic acid. The formulation met all essential quality parameters and demonstrated good stability and uniformity. The results highlight the importance of excipient selection and formulation optimization in the development of oral liquid dosage forms. This research provides a strong foundation for future studies aimed at improving hematinic formulations and contributes to the advancement of pharmaceutical formulation science.

ACKNOWLEDGEMENT

The authors are grateful to Anuradha College of Pharmacy, Chikhli for providing laboratory facilities and to the Principal Dr. R. H. Kale for his constant encouragement and guidance during the course of this study.

CONFLICT OF INTEREST

The authors declare no conflict of interest. This research received no external funding (Self-funded).

REFERENCES

1. World Health Organization. Iron deficiency anaemia: assessment, prevention and control. WHO; 2001.
2. World Health Organization. Worldwide prevalence of anaemia 1993–2005. WHO Press; 2008.
3. Hoffbrand AV, Moss PAH. Essential Haematology. 7th ed. Wiley Blackwell; 2016.
4. Aulton's Pharmaceutics. The Design and Manufacture of Medicines. Elsevier; 2018.
5. Ansel HC, Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Wolters Kluwer; 2018.
6. Lachman L, Lieberman HA. The Theory and Practice of Industrial Pharmacy. CBS Publishers; 2009.
7. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Ghaziabad; 2022.
8. United States Pharmacopeia. USP–NF. USP Convention; 2020.
9. Allen LV. Pharmaceutical Calculations. 14th ed. Elsevier; 2017.
10. Banker GS, Rhodes CT. Modern Pharmaceutics. CRC Press; 2002.
11. Satoskar RS, Bhandarkar SD. Pharmacology and Pharmacotherapeutics. Elsevier; 2019.
12. Tripathi KD. Essentials of Medical Pharmacology. Jaypee; 2019.
13. Rang HP, Dale MM. Pharmacology. Elsevier; 2016.
14. Guyton AC, Hall JE. Textbook of Medical Physiology. Elsevier; 2016.
15. O'Neil MJ. The Merck Index. 15th ed. Royal Society of Chemistry; 2013.
16. Allen LV. Liquid Dosage Forms. Pharmaceutical Press; 2013.
17. Aulton ME, Taylor KMG. Dosage Form Design. Elsevier; 2018.
18. Martin A. Physical Pharmacy. Lippincott Williams & Wilkins; 2011.
19. Rowe RC, Sheskey PJ. Handbook of Pharmaceutical Excipients. Pharmaceutical Press; 2012.
20. Lieberman HA. Pharmaceutical Dosage Forms: Tablets. CRC Press; 2008.
21. Sharma PP. Cosmetology: Theory and Practice. CBS Publishers; 2014.
22. Remington JP. Remington: The Science and Practice of Pharmacy. Pharmaceutical Press; 2013.
23. Sinko PJ. Martin’s Physical Pharmacy. Lippincott; 2011.
24. Swarbrick J. Encyclopedia of Pharmaceutical Technology. CRC Press; 2013.
25. Florence AT, Attwood D. Physicochemical Principles of Pharmacy. Pharmaceutical Press; 2016.
26. British Pharmacopoeia Commission. British Pharmacopoeia. 2020.
27. Liberman HA, Lachman L. Pharmaceutical Dosage Forms: Disperse Systems. CRC Press; 2005.
28. Allen LV. Compounding Formulations. Pharmaceutical Press; 2016.
29. Aulton ME. Pharmaceutics Principles and Applications. Elsevier; 2013.
30. Banker GS. Pharmaceutical Dosage Forms. Marcel Dekker; 2002.
31. Saha RN, Tiwari SB. Oral liquid dosage forms. Indian J Pharm Sci. 2002;64(1):1–6.
32. Patel RP, Patel MM. Formulation and evaluation of oral liquids. Int J Pharm Sci Rev Res. 2011;7(2):55–60.
33. Deshpande SG. Stability studies of pharmaceutical formulations. J Pharm Res. 2010;3(4):120–125.
34. Sharma V, Mishra DN. Syrup formulation and evaluation. Int J Pharm Sci. 2013;5(3):45–50.
35. Kumar R, Singh S. Liquid dosage forms and stability. Asian J Pharm. 2015;9(2):89–95.
36. Gupta P, Jain S. Pharmaceutical suspensions and syrups. Int J Pharm Sci. 2014;6(4):210–215.
37. Patel H, Shah D. Role of excipients in liquid dosage forms. Asian J Pharm Sci. 2016;10(2):89–95.
38. Joshi S, Mhatre M. Evaluation of syrup formulations. Int J Pharm Res Rev. 2015;4(6):23–30.
39. Sankar S, Mohanapriya S. Stability of vitamin formulations. Int J Pharm Sci. 2018;10(3):245–252.
40. Sharma P, Raghunandan D. Formulation optimization in syrups. J Pharm Res. 2020;14(1):12–19.
41. Jain NK. Controlled and Novel Drug Delivery Systems. CBS Publishers; 2016.
42. Brahmankar DM. Biopharmaceutics and Pharmacokinetics. Vallabh Prakashan; 2015.
43. Khar RK. Lachman’s Theory and Practice of Industrial Pharmacy. CBS Publishers; 2013.